Related Experiment Video
Updated: Jul 10, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Sung Hee Um1, Francesca Frigerio, Mitsuhiro Watanabe
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland.
Abstract:
Elucidating the signalling mechanisms by which obesity leads to impaired insulin action is critical in the development of therapeutic strategies for the treatment of diabetes. Recently, mice deficient for S6 Kinase 1 (S6K1), an effector of the mammalian target of rapamycin (mTOR) that acts to integrate nutrient and insulin signals, were shown to be hypoinsulinaemic, glucose intolerant and have reduced beta-cell mass. However, S6K1-deficient mice maintain normal glucose levels during fasting, suggesting hypersensitivity to insulin, raising the question of their metabolic fate as a function of age and diet. Here, we report that S6K1-deficient mice are protected against obesity owing to enhanced beta-oxidation. However on a high fat diet, levels of glucose and free fatty acids still rise in S6K1-deficient mice, resulting in insulin receptor desensitization. Nevertheless, S6K1-deficient mice remain sensitive to insulin owing to the apparent loss of a negative feedback loop from S6K1 to insulin receptor substrate 1 (IRS1), which blunts S307 and S636/S639 phosphorylation; sites involved in insulin resistance. Moreover, wild-type mice on a high fat diet as well as K/K A(y) and ob/ob (also known as Lep/Lep) mice-two genetic models of obesity-have markedly elevated S6K1 activity and, unlike S6K1-deficient mice, increased phosphorylation of IRS1 S307 and S636/S639. Thus under conditions of nutrient satiation S6K1 negatively regulates insulin signalling.
Insights
S6 Kinase 1 (S6K1) deficiency protects against obesity by enhancing fat breakdown. However, S6K1 negatively regulates insulin signaling, particularly under high-fat conditions, offering new therapeutic targets for diabetes.
Area of Science:
- Metabolic signaling pathways
- Obesity and diabetes research
- Mammalian Target of Rapamycin (mTOR) pathway
Background:
- Obesity impairs insulin action, contributing to diabetes.
- S6 Kinase 1 (S6K1) integrates nutrient and insulin signals.
- S6K1 deficiency in mice shows complex metabolic phenotypes, including glucose intolerance and altered insulin sensitivity.
Purpose of the Study:
- To investigate the role of S6K1 in metabolic regulation and insulin sensitivity.
- To determine the impact of S6K1 deficiency on obesity and response to high-fat diets.
- To elucidate the molecular mechanisms linking S6K1 to insulin resistance.
Main Methods:
- Analysis of S6K1-deficient mice under normal and high-fat diet conditions.
- Assessment of glucose homeostasis, free fatty acid levels, and beta-oxidation.
- Investigation of insulin receptor substrate 1 (IRS1) phosphorylation at key insulin resistance sites (S307 and S636/S639).
Main Results:
- S6K1-deficient mice are protected against diet-induced obesity due to enhanced beta-oxidation.
- Despite protection, high-fat diets lead to hyperglycemia and insulin receptor desensitization in S6K1-deficient mice.
- S6K1 deficiency prevents IRS1 phosphorylation at S307 and S636/S639, indicating preserved insulin sensitivity via a disrupted negative feedback loop.
- Obese wild-type and genetic obesity models exhibit elevated S6K1 activity and increased IRS1 phosphorylation.
Conclusions:
- S6K1 plays a critical role in negatively regulating insulin signaling under nutrient-rich conditions.
- Disruption of the S6K1-IRS1 negative feedback loop contributes to insulin sensitivity.
- Targeting S6K1 activity may offer therapeutic strategies for obesity and type 2 diabetes.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Other Disorders of Digestive System
Inborn Errors of Metabolism
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Sulfur Assimilation

